PMID: 11476121Jul 31, 2001Paper

Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America

Journal of Clinical Psychopharmacology
J A Costa e SilvaPierre V Tran

Abstract

Conventional antipsychotic agents can induce extrapyramidal symptoms (EPS) that may be alleviated by switching patients to novel agents such as olanzapine. Patients with schizophrenia and related disorders (ICD-10) who were taking haloperidol (N = 94; mean dose = 12.7 mg/day) and had EPS (Simpson-Angus Scale [SAS] > 3) were directly switched to 6 weeks of open-label olanzapine treatment (mean dose = 11.4 mg/day). There were significant mean improvements (p <0.001 for all measurements) from baseline to endpoint on the SAS (-9.69+/-5.33; percentage change, 87.2%), the Barnes Akathisia Scale (-1.00+/-1.19; percentage change, 82.5%), and the Abnormal Involuntary Movement Scale (-1.48+/-2.89; percentage change, 81.1%), and anticholinergic use decreased from 47.9% to 12.8% (mean baseline to endpoint change: -1.52+/-1.91-mg equivalents of benztropine; p < 0.001). Significant mean baseline to endpoint improvements (p < 0.001 for all measurements) were observed on the Positive and Negative Syndrome Scale (PANSS; -25.28+/-18.67; percentage change, 30.3%), the PANSS-extracted Brief Psychiatric Rating Scale (0-6 scale, -13.41+/-10.16; percentage change, 54.4%), and the Clinical Global Impressions Severity scale (-1.16+/-1.19; percentage ch...Continue Reading

References

Nov 1, 1978·The American Journal of Psychiatry·G GardosD Tarsy
Mar 1, 1976·Comprehensive Psychiatry·R B LacoursiereK Thompson
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Sep 1, 1981·The American Journal of Psychiatry·R L Binder, R Levy
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F P BymasterD T Wong
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·M E Stockton, K Rasmussen
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C M BeasleyS Hamilton
Feb 1, 1996·Progress in Neuro-psychopharmacology & Biological Psychiatry·P N Van HartenG E Matroos
Mar 1, 1996·Psychopharmacology·C M BeasleyS Hamilton
Jan 1, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·S NybergC Halldin
Jan 1, 1997·Archives of General Psychiatry·A C VigueraM Tohen
May 1, 1997·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·C M BeasleyJ N Beuzen
Feb 6, 1999·Journal of Clinical Psychopharmacology·R D Sanders, D Mossman
Jun 16, 1999·The Annals of Pharmacotherapy·J W LeeP G Dorson
Dec 6, 2000·The Journal of Clinical Psychiatry·B J KinonV L Stauffer

❮ Previous
Next ❯

Citations

Mar 21, 2007·Journal of Neural Transmission·S GebhardtF M Theisen
May 7, 2005·Journal of Clinical Psychopharmacology·Marius K NickelThomas H Loew
Aug 28, 2012·The Journal of Nervous and Mental Disease·Neil Krishan AggarwalRobert A Rosenheck
May 19, 2010·Pharmacology, Biochemistry, and Behavior·Esther M van der ZwaalRoger A H Adan
Oct 13, 2011·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Antonio DragoAlessandro Serretti
Oct 10, 2013·The International Journal of Neuropsychopharmacology·E M van der ZwaalR A H Adan
May 10, 2002·Pharmacoepidemiology and Drug Safety
Apr 23, 2005·The Cochrane Database of Systematic Reviews·L DugganS Indran
Mar 1, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Joseph M Pierre
Aug 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Sylvia ParkStephen B Soumerai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Related Papers

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
C M BeasleyJ N Beuzen
Progress in Neuro-psychopharmacology & Biological Psychiatry
A J GoudieHarry R Sumnall
American Journal of Public Health and the Nation's Health
R S Schilling
© 2021 Meta ULC. All rights reserved